SFI
AGIO icon

Susquehanna Fundamental Investments’s Agios Pharmaceuticals AGIO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,700
Closed -$795K – 1479
2020
Q3 		$795K Buy
22,700
+7,000
+45% +$307K 0.02% 724
2020
Q2 		$840K Buy
+15,700
New +$727K 0.04% 495

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Susquehanna Fundamental Investments's AGIO Position: Q4 2020 in Review

Susquehanna Fundamental Investments sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 22,700 shares — an estimated $795K sold.

Susquehanna Fundamental Investments first reported a position in AGIO in Q2 2020 and held it in 2 quarters. The position peaked at $840K in Q2 2020. 201 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Susquehanna Fundamental Investments reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 22,700 Agios Pharmaceuticals shares in Q4 2020, an estimated $795K.
  • Susquehanna Fundamental Investments first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Agios Pharmaceuticals position peaked at $840K in Q2 2020.
  • 201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2020, filed 16 Feb 2021.